Week Ending October 11, 2021

WHO announces the update of HCV guidelines on testing and treatment
“WHO has made available the membership of the Guidelines Development Group (GDG) for key updates of the 2018 WHO “Guidelines for the Care and Treatment of persons diagnosed with chronic hepatitis C virus infection” and the 2017 WHO “guidelines on hepatitis B and C testing”. This guideline update will be included in the planned 2022  “Consolidated Guidelines on Hepatitis prevention, diagnosis, treatment and care” which will incorporate both existing and new recommendations relating to chronic hepatitis B (HBV) and C virus (HCV) infection.”

Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018
“Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection carries substantial risk for all-cause mortality and liver-related morbidity and mortality, yet many persons coinfected with HIV/HCV remain untreated for HCV. We explored demographic, clinical, and sociodemographic factors among participants in routine HIV care associated with prescription of direct-acting antivirals (DAAs).”

Projected Long-Term Impact of the COVID-19 Pandemic on Outcomes Associated With Hepatitis C Virus
“An 18-month disruption in hepatitis C virus (HCV) testing, linkage, and treatment due to the COVID-19 pandemic resulted in fewer identified HCV cases and sustained virologic response (SVR), and an increase in cirrhosis and liver-related deaths, according to results of a study published in Clinical Infectious Diseases.”

Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore
“The landscape of treatment for hepatitis C virus (HCV) infection has evolved substantially since the introduction of highly effective HCV protease inhibitor therapies in 2011. The pace of change has increased rapidly as numerous new drugs with different mechanisms of action have become available over the past few years.”

The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interluekin-8 Expression
“A large amount of epidemiological evidence indicates that persistent HCV infection is the main risk factor for HCC. We aimed to study the effects of persistent HCV infection on the interaction of the virus and host cell to identify cancer gene profiles.”

Health Disparities Emerge Around Cancer Screening Eligibility
“Black patients are more likely to be excluded from cancer clinical trial screenings, generating health disparities.”

Unhealthy Alcohol Use Raises Mortality Rate in Cirrhosis Patients
“Alcohol use is directly tied to mortality rates and other negative liver disease outcomes for patients with cirrhosis.”